Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GDC-6988 · 1 trial · 2 indications
The AEs will be graded according to the DAIDS table for grading the severity. The severity level is graded from Grade 1 (mild) to 4 (Potentially Life-Threatening).
| Arm | Type | Description |
|---|---|---|
| GDC-6988 | EXPERIMENTAL | Participants in Cohort 1 will receive low-dose GDC-6988, twice a day (BID) on Day 1, followed by high-dose, BID on Day 2. Participants in Cohort 2 will receive low-dose, followed by high-dose GDC-6988, BID for 14 days. Participants in Cohorts 3 and 4 will receive low-dose GDC-6988, BID for 14 days. |
| Name | Type | Description |
|---|---|---|
| GDC-6988 | DRUG | GDC-6988 will be administered using a dry powder inhalation (DPI) device. |
Inclusion Criteria: * Percent predicted FEV1 ≥ 40% by spirometry during screening * Ability to demonstrate correct use of the smart DPI at screening, in the investigator's judgment * On a stable treatment regimen for muco-obstructive diseases for ≥ 28 days prior to initiation of study treatment and...
GDC-6988 is an investigational small molecule being developed for non-cystic fibrosis bronchiectasis, a respiratory condition. It is also being studied in chronic obstructive pulmonary disease. The drug is administered via inhalation and is currently in Phase 1 clinical development.
GDC-6988 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting a Phase 1 clinical trial to evaluate the safety and effects of the inhaled drug in participants with muco-obstructive disease.
GDC-6988 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to assess the safety and effects of the inhaled medication.
GDC-6988 is being studied in a Phase 1 clinical trial with the identifier NCT06603246. This trial is titled 'A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease' and is recruiting 128 participants in the United States.
GDC-6988 is administered via inhalation. The drug is being developed as an inhaled small molecule for the treatment of muco-obstructive diseases, including non-cystic fibrosis bronchiectasis and chronic obstructive pulmonary disease.